共 367 条
[91]
Sarneli A(undefined)Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM) undefined undefined undefined-undefined
[92]
Garibaldi C(undefined)Evaluation of kidney dose in neuroendocrine tumors patients after peptide receptor radionuclide therapy using undefined undefined undefined-undefined
[93]
Almond PR(undefined)Lu-DOTATATE undefined undefined undefined-undefined
[94]
Biggs PJ(undefined)Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy undefined undefined undefined-undefined
[95]
Coursey BM(undefined)A comparison of 2D and 3D kidney absorbed dose measures in patients receiving undefined undefined undefined-undefined
[96]
Hanson WF(undefined)Lu-DOTATATE undefined undefined undefined-undefined
[97]
Huq MS(undefined)In vivo binding of [ undefined undefined undefined-undefined
[98]
Nath R(undefined)Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours—impact of peptide mass undefined undefined undefined-undefined
[99]
Sandström M(undefined)Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy undefined undefined undefined-undefined
[100]
Ilan E(undefined)Treatment planning algorithm for peptide receptor radionuclide therapy considering multiple tumor lesions and organs at risk undefined undefined undefined-undefined